STAT+: New CAR-T company, Brainchild Bio, will focus first on brain tumors in children
Despite financial pressure to focus on adults, "we will go kids-first,” vows the founder of a new company that plans to design CAR-T immunotherapy for children with brain tumors.
About a decade ago, Mike Jensen, a pediatric oncologist at Seattle Children’s hospital, licensed to a startup his designs for a powerful new type of therapy, called CAR-T, that would re-engineer a child’s own immune cells to target cancer.
The deal proved be a mixed blessing. The therapy eventually reached market as Breyanzi, one of three CAR-Ts approved for adult leukemia. But it was never approved for childhood cancer.
The story was emblematic. Although the first CAR-T was approved in 2017 for children, after it cleared malignancies in some on the brink of death, researchers hoping to use the tool in other pediatric cancers have struggled.
What's Your Reaction?
